Phillip Md Et Al Frost Acquires 50,000 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 50,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was purchased at an average cost of $4.14 per share, with a total value of $207,000.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $12,705,457.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, February 2nd, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.30 per share, with a total value of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost bought 65,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.47 per share, with a total value of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost bought 55,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.90 per share, with a total value of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.89 per share, with a total value of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $4.40 per share, with a total value of $440,000.00.

Shares of Opko Health Inc. (OPK) opened at $4.14 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. Opko Health Inc. has a 52 week low of $4.01 and a 52 week high of $8.92. The company has a market capitalization of $2,427.82, a price-to-earnings ratio of -18.82 and a beta of 1.42.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The business had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same quarter in the prior year, the business posted ($0.03) earnings per share. The business’s revenue for the quarter was down 11.6% on a year-over-year basis. equities research analysts anticipate that Opko Health Inc. will post -0.27 earnings per share for the current year.

Several analysts recently weighed in on the company. BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Cantor Fitzgerald set a $20.00 price target on Opko Health and gave the stock a “buy” rating in a research note on Thursday, October 12th. Finally, Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Hold” and an average target price of $13.34.

Institutional investors and hedge funds have recently modified their holdings of the business. Crossmark Global Holdings Inc. purchased a new stake in Opko Health during the 3rd quarter valued at $118,000. State of Alaska Department of Revenue purchased a new stake in Opko Health during the 4th quarter valued at $144,000. The Manufacturers Life Insurance Company boosted its stake in Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,657 shares during the last quarter. Psagot Investment House Ltd. boosted its stake in Opko Health by 20.0% during the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 3,806 shares during the last quarter. Finally, Prudential Financial Inc. boosted its stake in Opko Health by 6.1% during the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 22.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/02/08/phillip-md-et-al-frost-acquires-50000-shares-of-opko-health-inc-opk-stock.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply